Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.

Breast Cancer Res · 2019 · PMC6751874 · PMID 31533777

Europe PMC DOI

hedged sentence

0.3280

closest p · 6.6× alpha

0.3280

boldest claim

The sentences

did not reach statistical significancep = 0.328not close (p > 0.1)

The anti-proliferative effect of LTZ+mVNB (− 73.2%) was numerically higher compared to LTZ (− 65.7%) but did not reach statistical significance ( p = 0.328).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.